The effect of metformin on the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide in adults with tuberculosis
4 affiliations
- 1Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
- 2The Aurum Institute, Johannesburg, South Africa
- 3Department of Medicine, UMass Chan Medical School, Worcester, Massachusetts, USA
- 4A*STAR Infectious Diseases Labs, Agency for Science Technology and Research (A*STAR), Singapore, Republic of Singapore
Abstract
Metformin is under investigation as adjunctive host-directed therapy for tuberculosis (TB), which might interact with first-line TB treatment. We used population pharmacokinetic modeling to assess whether metformin alters first-line TB-drug pharmacokinetics in HIV/TB-coinfected adults without diabetes. Rifampicin, isoniazid, and pyrazinamide pharmacokinetics were investigated in participants from a randomized clinical trial of adjunctive metformin (500 mg twice daily to week 12) in adults starting HIV-associated TB treatment. Antiretroviral therapy (ART)-naïve participants initiated dolutegravir-based ART within 8 weeks. Intensive and semi-intensive sampling was conducted at week 5; concentration–time data were analyzed using non-linear mixed-effects modeling. Data from 78 individuals (43 receiving metformin, median weight 60.8 kg, 62.8% male, 79.5% on ART) were analyzed. Rifampicin and pyrazinamide were described by one-compartment models with linear elimination; typical clearances were 15.8 L/h (95% CI: 13.5–18.7) and 3.88 L/h (95% CI: 3.54–4.08), respectively. Isoniazid followed a two-compartment model with a mixture model for acetylator status; clearance was 10.5 L/h (95% CI: 9.44–11.9) in slow acetylators and 28.8 L/h (95% CI: 25.6–31.0) in fast/intermediate acetylators. Metformin reduced isoniazid bioavailability by 15.6% (95% CI: 4.45–26.4%, P < 0.009) and rifampicin bioavailability by 24.0% (95% CI: 7.83–36.3%, P < 0.007), decreasing the area under the curve from 0 to 24 h from 18.2 to 15.6 mg·h/L and from 35.9 to 27.1 mg·h/L, respectively. No significant effect on pyrazinamide was detected. We found that non-diabetic patients on metformin had lower isoniazid and rifampicin bioavailability. Lowered rifampicin exposure might be clinically relevant; simulations suggest that this could be offset by a single 150 mg rifampicin dose.
CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT04930744.
Related
- The Blind Spot of GeneXpert MTB/RIF: Isoniazid‐Resistant, Rifampicin‐Susceptible Tuberculosis Detected on Phenotypic Drug Susceptibility Testing
- Clofazimine pharmacokinetics in novel rifampicin-resistant tuberculosis regimens: an analysis of the endTB and endTB-Q trials
- The Impact of Isoniazid Preventive Therapy on Tuberculosis Infection and Disease Progression
- The impact of ionic liquid formation on the activity, solubility and pharmacokinetics of rifampicin
- Treatment outcomes and post-treatment mortality among people with multidrug/rifampicin-resistant tuberculosis in Sierra Leone: a national cohort study
BibTeX
@article{rossouw2026effect,
title = {{The effect of metformin on the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide in adults with tuberculosis}},
author = {Jacques Rossouw and Robert Wallis and Hardy Kornfeld and Amit Singhal and Gary Maartens and Lubbe Wiesner and Paolo Denti and Roeland E. Wasmann},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
month = aug,
doi = {10.1128/aac.00748-26},
url = {https://doi.org/10.1128/aac.00748-26},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The effect of metformin on the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide in adults with tuberculosis
AU - Jacques Rossouw
AU - Robert Wallis
AU - Hardy Kornfeld
AU - Amit Singhal
AU - Gary Maartens
AU - Lubbe Wiesner
AU - Paolo Denti
AU - Roeland E. Wasmann
PY - 2026
DA - 2026/08/06
JO - Antimicrobial Agents and Chemotherapy
DO - 10.1128/aac.00748-26
UR - https://doi.org/10.1128/aac.00748-26
AB - Metformin is under investigation as adjunctive host-directed therapy for tuberculosis (TB), which might interact with first-line TB treatment. We used population pharmacokinetic modeling to assess whether metformin alters first-line TB-drug pharmacokinetics in HIV/TB-coinfected adults without diabetes. Rifampicin, isoniazid, and pyrazinamide pharmacokinetics were investigated in participants from a randomized clinical trial of adjunctive metformin (500 mg twice daily to week 12) in adults starting HIV-associated TB treatment. Antiretroviral therapy (ART)-naïve participants initiated dolutegravir-based ART within 8 weeks. Intensive and semi-intensive sampling was conducted at week 5; concentration–time data were analyzed using non-linear mixed-effects modeling. Data from 78 individuals (43 receiving metformin, median weight 60.8 kg, 62.8% male, 79.5% on ART) were analyzed. Rifampicin and pyrazinamide were described by one-compartment models with linear elimination; typical clearances were 15.8 L/h (95% CI: 13.5–18.7) and 3.88 L/h (95% CI: 3.54–4.08), respectively. Isoniazid followed a two-compartment model with a mixture model for acetylator status; clearance was 10.5 L/h (95% CI: 9.44–11.9) in slow acetylators and 28.8 L/h (95% CI: 25.6–31.0) in fast/intermediate acetylators. Metformin reduced isoniazid bioavailability by 15.6% (95% CI: 4.45–26.4%, P < 0.009) and rifampicin bioavailability by 24.0% (95% CI: 7.83–36.3%, P < 0.007), decreasing the area under the curve from 0 to 24 h from 18.2 to 15.6 mg·h/L and from 35.9 to 27.1 mg·h/L, respectively. No significant effect on pyrazinamide was detected. We found that non-diabetic patients on metformin had lower isoniazid and rifampicin bioavailability. Lowered rifampicin exposure might be clinically relevant; simulations suggest that this could be offset by a single 150 mg rifampicin dose. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT04930744.
SN - 0066-4804
SN - 1098-6596
ER -